403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Regeneus Ltd (ASX:RGS) Edison Investment Report Issued
(MENAFN- ABN Newswire) Sydney, Sep 11, 2017 AEST (ABN Newswire) - The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.
Please contact or connect with Regeneus via social media platforms below if you'd like further information.
To view the Edison Report, please visit:
About Regeneus Ltd
Please contact or connect with Regeneus via social media platforms below if you'd like further information.
To view the Edison Report, please visit:
About Regeneus Ltd
() is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment